文献速递心外重症与机械循环支持瓣膜外科

连续流左心室辅助装置植入同期二尖瓣修复是否有必要?

Concomitant mitral repair and continuous-flow left ventricular assist devices: Is it warranted?
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-04-22

本研究纳入374例连续流左心室辅助装置植入患者中115例术前二尖瓣反流大于中度者,比较同期二尖瓣修复(52例)与未修复(63例)的结局。修复组在装置支持期间发生中度或重度二尖瓣反流的 odds 降低86%,且晚期右心衰竭发生率更低。同期二尖瓣修复似乎有效控制装置植入后二尖瓣反流,并可能减少晚期右心衰竭。

要点

  • 同期二尖瓣修复使装置支持期间中度或重度二尖瓣反流风险降低86%。
  • 多变量竞争风险回归显示二尖瓣修复是晚期右心衰竭的保护因素(HR 0.16)。

核心结论

  • 同期二尖瓣修复在控制装置植入后二尖瓣反流方面似乎有效。
  • 修复组晚期右心衰竭发生率更低,挑战了同期二尖瓣修复不必要的观点。

研究设计与样本

  • 纳入115例术前二尖瓣反流大于中度者,其中同期修复组52例(45.2%),未修复组63例(54.8%)。

主要发现

  • 修复组更多接受destination therapy(48.1% vs 11.1%,P<.001),体外循环时间更长(125 vs 89分钟,P<.001)。
  • 广义混合效应模型显示修复组装置支持期间发生中度或重度二尖瓣反流的 odds 降低86%(P<.001)。
  • 存活出院患者中,修复组1例(2.2%)、未修复组8例(13.6%)发生晚期右心衰竭(P=.039),再入院率分别为0.03 vs 0.15次/患者年(P=.011)。
  • 多变量竞争风险回归显示二尖瓣修复为晚期右心衰竭的保护因素(HR 0.16,95%CI 0.03-0.94,P=.042)。

临床怎么用

  • 对于术前二尖瓣反流大于中度的连续流左心室辅助装置候选者,可考虑同期二尖瓣修复以控制术后二尖瓣反流并降低晚期右心衰竭风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-existing mitral pathology is common in patients undergoing continuous-flow left ventricular assist device implantation. We sought to investigate whether concurrent mitral repair confers any advantage. METHODS: From March 2004 to October 2014, 374 patients received a continuous-flow left ventricular assist device. Of these, a total of 115 patients with pre-existing mitral regurgitation (MR) greater than moderate were identified and included in the analysis. Outcomes were compared between patients with concurrent mitral repair (n = 52 [45.2%]; Group A) and without repair (n = 63 [54.8%]; Group B). RESULTS: The mean age was 56.8 years and 25 (21.5%) were women. Patients in Group A were more likely to have undergone destination therapy (48.1% vs 11.1%; P < .001) and had a greater cardiopulmonary bypass time (125 vs 89 minutes; P < .001) than did patients in Group B. Longitudinal analysis using a generalized mixed-effects model demonstrated the odds of developing moderate or severe MR during device support were 86% lower for Group A patients (P < .001). Among those who were discharged alive, 9 (8.6%)-consisting of 1 (2.2%) in Group A and 8 (13.6%) in Group B (P = .039)-developed late right heart failure requiring a total of 13 readmissions (0.03 vs 0.15 readmissions per patient-year; P = .011). Multivariable competing risks regression revealed mitral repair to be a protective factor (hazard ratio, 0.16; 95% confidence interval, 0.03-0.94; P = .042) for late right heart failure occurrence. CONCLUSIONS: Concurrent mitral repair appears to be efficacious in controlling MR after device implant. The fact that repaired patients developed late right heart failure less frequently than did patients without repair challenges the notion that concurrent mitral repair is unwarranted.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Fukuhara S, Takeda K, Chiuzan C, et al. Concomitant mitral repair and continuous-flow left ventricular assist devices: Is it warranted? J Thorac Cardiovasc Surg. 2017. PMID: 28800891. doi:10.1016/j.jtcvs.2017.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。